Congratulations to Maureen Hennessey for being named to the 2022 PharmaVoice100, as a DE&I Champion! Maureen has been fearless in her dedication and pursuit to address the gaps that exist in today’s healthcare system that lead to medication non-adherence and impact social determinants of health.
Check out our September Events Calendar, and stay up to date with all of the upcoming and on-demand Precision events and thought leadership!
Changes in climate and extreme weather affect every stakeholder in the healthcare system, not just the physicians on the front lines. Precision's Cynthia Miller suggests we need a patient focused strategy to manage environmental risk and offers solutions that align with incentives.
Earlier this year, Precision Value & Health, in association with Precision ADVANCE, hosted an in-depth, live roundtable: The Future Treatment and Access Landscape for Cell and Gene Therapies
Don’t miss any of our upcoming Precision Value & Health events! Check out our monthly marketing activities calendar to stay ahead of upcoming dates!
While the pandemic exposed the nation’s enormous health disparities, it also led to significant policies that increased the number of insured Americans by expanding enrollment in Medicaid and Health Exchange plans. These advancements are at risk. Precision's Cynthia Miller and Maureen Hennessey discuss why discontinuing the policy changes will contribute to health inequities in myriad ways, and identify the essential role pharmaceutical companies can play in mitigating the impact.
We are honored to announce that PRECISIONvalue has been named as a finalist for the 2022 MM+M Awards in the Market Access Maven category! Congratulations to all finalists and thank you to our clients and team members for their roles in this impressive achievement.
The exponential spending growth in oncology has resulted in myriad utilization management strategies by both payers and providers to control costs, especially drug costs. Precision's Julianna Kula, Bruce Edelen, Ronald Schleif, Jeffrey Becker, Mark Urban, and Elizabeth Oyekan explore current and emerging drug utilization management strategies being employed to help curtail oncology costs without adversely impacting patient quality and outcomes.
More pushback against copay programs likely on the horizon: Precision's Ryan Cox and Reta Mourad, PharmD, FNTP discuss why a federal court's decision striking down a CMS rule that would have narrowed the exclusions from Medicaid best price for manufacturer-provided patient-assistance programs, as well as a recent pharma lawsuit against a maximizer company, could spur more states to take action of their own.
Orphan drugs for rare diseases are now frequently found in big pharma pipelines. Payers have had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline. Precision's Phil Cyr and Erin Lopata weigh in on new ways to pay for them.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
